Medlab Clinical (ASX: MDC)


Medlab Clinical (ASX: MDC) is an Australian based medical life science company, developing therapeutic pathways for diagnosed chronic diseases. www.medlab.co

Medlab Clinical ASX MDC NanaBis Observational Study cannabinoid treatment cancer bone pain

Medlab Clinical’s NanaBis drug dramatically improves cancer bone pain for first patient group in treatment study

Australian biotech Medlab Clinical (ASX: MDC) has reported the first cohort of patients undergoing a 12-month study of its NanaBis cannabinoid t...
Medlab Clinical NanoCelle European Patent Office ASX MDC

Medlab Clinical to be granted European patent for NanoCelle drug delivery platform

Australian biotech Medlab Clinical (ASX: MDC) has announced it has received notice from the European Patent Office of its intention to grant a p...
Medlab Clinical ASX MDC placement Cheryl Maley

Medlab Clinical tops up cash reserves, builds board capabilities with new appointment

Medlab Clinical (ASX: MDC) has topped up its cash reserves with a $15 million placement, while boosting its board expertise with the appointment...
Medlab Clinical ASX 2021 H2 H1 NanaBis NanoCBD

Medlab Clinical heads into H2 2021 with strong momentum following ‘very pleasing’ H1

Biotech Medlab Clinical (ASX: MDC) has ended the H1 of the 2021 financial year with $6.8 million cash in the bank with increasing early revenue ...
Medlab ASX MDC Arrotex Australia Group NanoCBD TGA

Medlab Clinical partners with Arrotex to accelerate NanoCBD availability in Australian pharmacies

Medlab Clinical (ASX: MDC) has collared a heads of agreement with Australia’s largest generic over-the-counter (OTC) supplier Arrotex to fast-tr...
Medlab Clinical MDC ASX NRGBiotic Phase IIa Depression trial

Medlab Clinical’s probiotic NRGBiotic found to assist in reducing depression symptoms

Preliminary analysis of a phase IIa trial using Medlab Clinical’s (ASX: MDC) probiotic NRGBiotic has revealed a “significant” reduction in depre...
Medlab Clinical ASX MDC NanaBis non-opioid pain treatment phase three cancer NanoCelle

Medlab Clinical to confirm NanaBis’ potential as non-opioid pain treatment in phase three trials

Australian biotech Medlab Clinical (ASX: MDC) could be the world’s first drug developer to have a registered cannabis-based medicine that outper...
Medlab Clinical ASX MDC NanaBis FDA new drug status IND approval

Medlab Clinical collars US FDA IND approval for cancer-pain treatment NanaBis

Medlab Clinical (ASX: MDC) has collared clinical investigational new drug status from the United States Food and Drug Administration for its lea...
TGA cannabis changes pot stocks Therapeutic Goods Administration cannabidiol CBD over-the-counter OTC

Drawbacks of the TGA’s cannabis changes for listed pot stocks

Having been subject to a harsh reality check over the last year or so, the ASX-listed cannabis sector is applauding the local medicine regulator...
Medlab Clinical NanaBis ASX MDC cancer trial results Royal North Shore Hospital

Medlab’s NanaBis spray deemed safe for chronic pain management in patients with advanced breast and prostate cancers

Results from an advanced cancer pain clinical trial using NanaBis oro-buccal spray developed by Medlab Clinical (ASX: MDC) has found the novel d...
Medlab Clinical ASX MDC trial Nanostat spray improved metabolic functioning tablet version atorvastatin

Medlab trial shows Nanostat spray delivers improved metabolic functioning over tablet version

Australian-based Medlab Clinical (ASX: MDC) has reported results of a bioequivalence trial involving an orobuccal spray version of its Nanostat ...
Medlab Clinical ASX MDC cannabis export licence

Export licence granted to Medlab in development of cannabis pain management products

Australian life sciences company Medlab Clinical (ASX: MDC) has been granted a licence to export cannabis relating to the development of its Nan...
Medlab Clinical ASX MDC positive feedback doctors prescribing cannabis cancer pain

Medlab Clinical gets positive feedback from doctors prescribing cannabis for cancer pain

Medlab Clinical (ASX: MDC) has claimed it has received positive feedback from doctors prescribing its cannabis-based medicine NanaBis for the pa...